Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 10, 2011

Premium

Title: Nanoparticles for Protein/Peptide Delivery and Delivery Means Thereof

Patent Number: 7,901,711

Filed: Oct. 16, 2007

Lead Inventor: Hsing-Wen Sung, GP Medical

The invention comprises a “biodegradable nanoparticle for use in nanoparticle projectile bombardment as a carrier for administering proteins, peptides, or siRNAs transdermally to an animal subject, the patent's abstract states. “The nanoparticles are composed of positively charged chitosan substrate, negatively charged core substrate complexed with chitosan, and encapsulated bioactive agents.”


Title: Compositions Comprising Inhibitors of RNA Binding Proteins and Methods of Producing and Using Same

Patent Number: 7,902,166

Filed: April 20, 2009

Lead Inventor: Courtney Houchen, University of Oklahoma

The invention comprises compositions, specifically siRNAs, for “inhibiting RNA binding proteins, as well as methods of producing and using the same,” the patent's abstract states.


Title: Compounds and Methods for Down-Regulating Wrap53 Protein by RNA Interference

Patent Number: 7,902,167

Filed: April 10, 2008

Lead Inventor: Marianne Farnebo, Aprea

The invention, the patent's abstract states, comprises a “small nucleic acid molecule that down-regulates expression of Wrap53 gene via RNA interference, wherein at least one strand of … [the] nucleic acid molecule is about 15 to about 30 nucleotides in length … [and one] comprises a nucleotide sequence having sufficient complementarity to an RNA of said Wrap53 gene for the small nucleic acid molecule to direct cleavage of said RNA via RNA interference, for use as a medicament.”


Title: Compositions and Methods for Inhibiting Expression of Nav1.8 Gene

Patent Number: 7,902,168

Filed: June 18, 2009

Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the Nav1.8 gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene,” the patent's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.”


Title: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure

Patent Number: 7,902,169

Filed: Sept. 21, 2009

Lead Inventor: Ana Jimenez, Sylentis

The invention relates to “methods and compositions that decrease intraocular pressure of the eye,” the patent's abstract states. “The compositions of the invention comprise short interfering nucleic acid molecules including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye condition displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.”


Title: Inhibition of Viral Gene Expression Using Small Interfering RNA

Patent Number: 7,902,351

Filed: June 1, 2006

Lead Inventor: Roger Kaspar, SomaGenics

“The invention provides methods, compositions, and kits comprising small interfering RNA that are useful for inhibition of viral-mediated gene expression,” the patent's abstract states. “Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targeting the internal ribosome entry site sequence of HCV are described.”


Title: Isolated Nucleic Acid Duplex for Reducing Huntington Gene Expression

Patent Number: 7,902,352

Filed: Aug. 9, 2006

Lead Inventor: William Kaemmerer, Medtronic

The invention, the patent's abstract states, comprises “sequences, molecules, and methods used to suppress the expression of [Huntington's disease] genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of [Huntington's disease] and can also provide a treatment for this disease by reducing [huntingtin] mRNA without causing death, locomotor impairment, or cellular alterations.”


Title: microRNA Signatures Associated with Human Chronic Lymphocytic Leukemia and Uses Thereof

Application Number: 20110052502

Filed: Feb. 27, 2009

Lead Inventor: Carlo Croce, Ohio State University

The invention comprises “methods and compositions for the diagnosis, prognosis, and/or treatment of leukemia associated diseases,” according to the patent application's abstract.


Title: Compositions, Methods, and Systems for siRNA Delivery

Application Number: 20110052666

Filed: Sept. 3, 2009

Lead Inventor: William Kaemmerer, Medtronic

The invention comprises “silencer expression cassettes for delivery of RNAi therapy,” the patent application's abstract states. “The silencer cassettes of the instant invention encode an RNAi agent and lack means for replication within a host cell, inverted terminal repeats and further lacking one or more selectable markers. Optionally, the silencer cassettes lack CpG dinucleotides and/or the RNAi agent is within a scaffold of a naturally occurring [microRNA]. The composition comprising the silencer cassettes of the ... invention, as well as methods of use and suitable systems are also provided.”


Title: Method for Enzymatic Synthesis of Chemically Modified RNA

Application Number: 20110053226

Filed: June 9, 2009

Inventor: Jacques Rohayem, RiboxX

The invention, the patent application's abstract states, relates to “a method for enzymatically synthesizing chemically modified RNA by using RNA-dependent RNA polymerases, especially RdRps from viruses of the Caliciviridae family. The method of the … invention is particularly useful for preparing RNA molecules of increased stability especially with respect to RNA degradation, for example for in vivo applications. Further subject matter of the ... invention relates to a kit for carrying out the enzymatic synthesis of the chemically modified RNA.”


Title: Compositions Comprising Nuclear Factor-Kappa B siRNA and Methods of Use

Application Number: 20110053861

Filed: March 12, 2009

Lead Inventor: Frank Xie, Intradigm (Silence Therapeutics)

The invention comprises “siRNA nucleic acid molecules that inhibit NF-kappa B expression,” the patent application's abstract states. “Methods of using the nucleic acid molecules are also provided.”


Title: Compositions Comprising Survivin siRNA and Methods of Use Thereof

Application Number: 20110053862

Filed: March 9, 2009

Lead Inventor: Frank Xie, Intradigm (Silence Therapeutics)

The invention comprises “siRNA nucleic acid molecules that inhibit survivin expression,” according to the patent application's abstract. “Methods of using the nucleic acid molecules are also provided.”


Title: 6-Disubstituted or Unsaturated Bicyclic Nucleic Acid Analogs

Application Number: 20110053881

Filed: July 1, 2008

Lead Inventor: Punit Seth, Isis Pharmaceuticals

The patent application, its abstract states, “describes 6-disubstituted bicyclic nucleosides, oligomeric compounds prepared therefrom, and methods of using the oligomeric compounds. More particularly, the 6-disubstituted bicyclic nucleosides each comprise a 2'-O--C(Ri)(R2)-4' or 2'-O--C=(R3)(R.4)-4' bridge wherein each R is, independently, a substituent group and Ri and R2 include H. The 6-disubstituted bicyclic nucleosides are useful for enhancing properties of oligomeric compounds including nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.”


Title: Polynucleotides for Causing RNA Interference and Method for Inhibiting Gene Expression Using the Same

Application Number: 20110054005

Filed: May 11, 2010

Lead Inventor: Yuki Naito, University of Tokyo

The invention comprises “a polynucleotide that not only has a high RNA interference effect on its target gene, but also has a very small risk of causing RNA interference against a gene unrelated to the target gene,” the patent application's abstract states.


Title: Regulation of Oncogenes by microRNAs

Application Number: 20110054006

Filed: April 26, 2010

Lead Inventor: Frank Slack, Yale University

The patent application, its abstract states, claims “naturally occurring miRNAs that regulate human oncogenes and methods of use thereof. ... Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions are administered to a subject prior to administration of a cytotoxic therapy in an amount effective to sensitize cells or tissues to be treated to the effects of the cytotoxic therapy.”


Title: RNAi Inhibition of Serum Amyloid for a Treatment of Glaucoma

Application Number: 20110054008

Filed: Oct. 26, 2010

Lead Inventor: Abbot Clark, Alcon

“RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression,” the patent application's abstract states.


Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Prostate-Related Disorders

Application Number: 20110054009

Filed: Feb. 27, 2009

Lead Inventor: Carlo Croce, Ohio State University

The patent application, its abstract states, claims “methods and compositions for the diagnosis, prognosis, and/or treatment of prostate-associated disorders.”


Title: Methods and Compositions for Increasing Gene Expression

Application Number: 20110054012

Filed: Dec. 23, 2008

Lead Inventor: Robert Place, University of California, San Francisco

The invention provides “compositions, pharmaceutical preparations, kits, and methods for increasing expression of a gene product in a cell by contacting the cell with a microRNA molecule comprising a ribonucleic strand that is complementary to a non-coding nucleic acid sequence of the gene,” the patent application's abstract states.


Title: RNA Interference-Mediating Small RNA Molecules

Application Number: 20110054159

Filed: Aug. 7, 2009

Lead Inventor: Thomas Tuschl, Max Planck Institute

“Double-stranded RNA induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference,” the patent application's abstract states. “Using a Drosophila in vitro system, we demonstrate that 19-23 [nucleotide long] short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced [small interfering ribonucleoprotein particle] complex.”


Title: Therapeutic Compositions

Application Number: 20110054160

Filed: April 6, 2010

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention “relates to therapeutic siRNA agents and methods of making and using the agents,” the patent application's abstract states.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.